The committee empaneled to advise the California Division of Workers’ Compensation on evidence-based updates to the prescription drug formulary will discuss whether to take into consideration costs when deciding which medications would be exempted from prospective review, during a July 24 meeting in Oakland.
One item on the agenda for the Pharmacy and Therapeutics Committee meeting is to review a proposal to modify the criteria used to determine which drugs will be classified as “exempt.”
Drugs designated as non-exempt, as well as those not listed in the formulary, are...
Comments